EMT is a developmental program enabling epithelial cells to acquire migratory and invasive properties through loss of E-cadherin, gain of vimentin, and activation of transcription factors (Snail, Slug, Twist). In cancer, EMT enables metastatic dissemination; in normal physiology, it drives gastrulation and wound healing.
Study the molecular events: loss of cell-cell adhesion, activation of β-catenin signaling, upregulation of matrix metalloproteinases. Understand that EMT is reversible (MET) and that partial EMT may be most metastasis-competent.
EMT is not mandatory for metastasis—collective migration and dissemination without EMT can occur. Not all mesenchymal-appearing cells are truly EMT-derived; they may be fibroblasts or immune cells.
Epithelial cells are built for stability. You know from your study of cell adhesion molecules that epithelial sheets are held together by E-cadherin at adherens junctions, with tight junctions sealing the perimeter and desmosomes distributing mechanical stress across the sheet. This architecture is optimized for barrier function — not movement. Epithelial-mesenchymal transition (EMT) is the coordinated dissolution of this architecture, allowing a stationary epithelial cell to become a migratory, invasive cell that can move through extracellular matrix and survive outside its native tissue environment. The transition is not a random breakdown; it is a regulated developmental program repurposed in cancer.
The molecular events proceed in a defined sequence. The key initiating step is repression of E-cadherin — the adhesion molecule that anchors cells to their neighbors. Transcription factors Snail, Slug, and Twist directly repress the E-cadherin gene, dissolving adherens junctions and releasing cells from the epithelial sheet. Simultaneously, the cytoskeleton is reorganized: the cortical actin network characteristic of epithelial cells is replaced by stress fibers and vimentin, an intermediate filament associated with mesenchymal cells and cell motility. The cell also upregulates matrix metalloproteinases (MMPs), enzymes that digest basement membrane and extracellular matrix, clearing a physical path for migration. The result is a cell that has lost polarity, detached from neighbors, and acquired the migratory machinery to invade surrounding tissue.
In normal development, EMT is indispensable. During gastrulation, epithelial cells of the epiblast undergo EMT to form the mesoderm and endoderm — the precursors of muscle, bone, connective tissue, and internal organs. Later, EMT drives neural crest cell migration, which gives rise to peripheral neurons, melanocytes, and craniofacial bones. In wound healing, keratinocytes at wound edges partially undergo EMT to migrate across the wound bed before reverting to an epithelial phenotype once closure is complete. EMT is therefore not intrinsically pathological — it is a repurposed embryonic program.
In cancer, the same program enables metastatic dissemination. Tumor cells in a primary epithelial cancer (carcinoma) activate EMT transcription factors — often triggered by TGF-β, Wnt, Notch, or HIF-1α signals from the tumor microenvironment. The result is invasion through the basement membrane, entry into blood or lymphatic vessels (intravasation), survival in circulation, and extravasation at distant sites. At the metastatic site, many disseminated tumor cells undergo the reverse process — mesenchymal-epithelial transition (MET) — to re-establish an epithelial phenotype and colonize the new tissue. This reversibility means EMT is not a permanent cell-fate switch but a dynamic state. Importantly, research suggests that partial EMT — where cells are neither fully epithelial nor fully mesenchymal but retain aspects of both — may be the most metastasis-competent state, because it combines cohesive collective migration with individual invasive capacity. Full EMT may actually reduce metastatic seeding efficiency in some contexts, complicating the simple narrative that more EMT equals more metastasis.
No topics depend on this one yet.